Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galapagos : Gets European Medicines Agency's Positive Opinion on Ulcerative Colitis Drug Candidate

09/17/2021 | 08:50am EDT


ę MT Newswires 2021
All news about GALAPAGOS NV
10/06GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
PU
10/06GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
PU
10/04GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
AQ
10/04Galapagos Presents New Data from the Selection Phase 3 Program At the United European G..
CI
10/04GALAPAGOS : Completes Patient Recruitment In Late-Stage Inflammatory Bowel Disease Study
MT
10/04GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
AQ
10/04Galapagos Announces Completion of Patient Enrollment for Diversity Phase 3 Study with F..
CI
09/21GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
09/21GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises
PU
09/21GALAPAGOS : Issues New Shares For Subscription Right Exercises
MT
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2021 520 M 603 M 603 M
Net income 2021 -220 M -255 M -255 M
Net cash 2021 4 040 M 4 689 M 4 689 M
P/E ratio 2021 -15,3x
Yield 2021 -
Capitalization 2 934 M 3 401 M 3 405 M
EV / Sales 2021 -2,13x
EV / Sales 2022 -1,49x
Nbr of Employees 1 397
Free-Float 74,5%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 44,78 €
Average target price 56,00 €
Spread / Average Target 25,1%
EPS Revisions
Managers and Directors
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj Bhikhu Parekh Chairman
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-44.36%3 462
MODERNA, INC.226.29%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.41.93%48 923
SEAGEN INC.-0.30%32 330
CELLTRION, INC.-39.00%26 036